Managed Care - July 2008 - (Page 35) Confidence that breast cancer treatment is tailored for her. Oncotype DX® is the leading clinically validated, multi-gene assay that quantifies the likelihood of distant breast cancer recurrence. It delivers: • An Individualized Recurrence Score™ Result — Based on the expression of 21 genes from a sample of a patient’s tumor tissue • A Chemotherapy Benefit Assessment — Predicts the magnitude of benefit from chemotherapy • Confidence — Performance exceeds standard measures such as tumor size, tumor grade, and patient age in terms of either predictive power or reproducibility Strength in Numbers Learn how Oncotype DX can provide valuable insight when making adjuvant therapy decisions at www.oncotypeDX.com, or call (866) ONCOTYPE (866-662-6897). Oncotype DX is a registered trademark and Recurrence Score is a trademark of Genomic Health, Inc. ©2008 Genomic Health, Inc. All rights reserved. 3/08 http://www.oncotypeDX.com http://www.oncotypeDX.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.